Crescent Biopharma, Inc.
NASDAQ Capital MarketTotal Valuation
Crescent Biopharma, Inc. carries a market capitalization of 458.80M, placing it among publicly traded companies globally. Its enterprise value stands at 142.29M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 458.80M |
| Enterprise Value | 142.29M |
Share Statistics
Crescent Biopharma, Inc. currently has 27.57M shares outstanding.
| Shares Outstanding | 27.57M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 27.43, and the price-to-book ratio stands at -1.67.
| PE Ratio | N/A |
| PS Ratio | 27.43 |
| PB Ratio | -1.67 |
| P/TBV Ratio | 1.81 |
| P/FCF Ratio | -5.38 |
| P/OCF Ratio | -4.68 |
Enterprise Valuation
| EV / Sales | 11.97 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Crescent Biopharma, Inc. maintains a current ratio of 13.78, meaning it holds 13.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.84, indicating moderate leverage, while an interest coverage ratio of -151.90 demonstrates limited ability to service its debt obligations.
| Current Ratio | 13.78 |
| Quick Ratio | 13.33 |
| Debt / Equity | 0.84 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -151.90 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -290.91 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Crescent Biopharma, Inc.'s stock has gained approximately 26.06061% over the past 52 weeks. The 50-day moving average sits at 18.03, while the 200-day moving average is 14.68.
| Beta (5Y) | N/A |
| 52-Week Price Change | 26.06061% |
| 50-Day Moving Average | 18.03 |
| 200-Day Moving Average | 14.68 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Crescent Biopharma, Inc. generated 11.88M in revenue and converted that into -162.08M in net income, yielding earnings per share of -9.14. EBITDA reached -162.99M, while operating income came in at -163.14M.
| Revenue | 11.88M |
| Gross Profit | N/A |
| Operating Income | -163.14M |
| Pretax Income | -160.08M |
| Net Income | -162.08M |
| EBITDA | -162.99M |
| EBIT | -163.14M |
| Earnings Per Share (EPS) | -9.14 |
Balance Sheet
Crescent Biopharma, Inc. holds 189.16M in cash and equivalents against 1.54M in total debt, resulting in a net debt position of -189.16M. Total book value stands at -195.06M, with working capital of 181.37M providing operational flexibility.
| Cash & Cash Equivalents | 189.16M |
| Total Debt | 1.54M |
| Net Debt | -189.16M |
| Equity (Book Value) | -195.06M |
| Book Value Per Share | -10.99 |
| Working Capital | 181.37M |
Cash Flow
Crescent Biopharma, Inc. produced -69.62M in operating cash flow over the past twelve months. After subtracting -9.07M in capital expenditures, free cash flow totaled -78.68M - equivalent to -4.44 per share.
| Operating Cash Flow | -69.62M |
| Capital Expenditures | -9.07M |
| Free Cash Flow | -78.68M |
| FCF Per Share | -4.44 |
Margins
Crescent Biopharma, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -1,372.85 and net profit margin of -1,363.94 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -1,372.85 |
| Pretax Margin | -1,347.11 |
| Profit Margin | -1,363.94 |
| EBITDA Margin | -1,371.61 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -97.43 |
| FCF Yield | -18.58 |
Stock Splits
Crescent Biopharma, Inc.'s most recent stock split took place on June 16, 2025 with a 100:1 split ratio.
| Last Split Date | 6/16/2025 |
| Split Ratio | 100:1 |
Scores
Crescent Biopharma, Inc. posts an Altman Z-Score of 9.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 9.87 |